HilleVax, Inc.

NASDAQ•HLVX

CEO: Dr. Robert M. Hershberg M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2022-04-29

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Contact Information

321 Harrison Avenue, 5th floor, Boston, MA, 02118, United States

617-213-5054

www.hillevax.com

Market Cap

$104.76M

P/E (TTM)

-1.5

17.9

Dividend Yield

52W High

$2.17

52W Low

$1.34

52W Range

90%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q2 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.11-86.75%

4-Quarter Trend

FCF

-$789.00K-97.36%

4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

R&D Spending Significantly Reduced Six-month R&D expenses fell $49.3M to $3.311M, driven by HIL-214 discontinuation decisions in 2024.

Net Loss Improvement Strong Net loss for six months narrowed substantially to $(11.327)M versus $(87.497)M last year due to lower operating costs.

Cash Position At Period End Total cash, cash equivalents, and restricted cash stood at $60.308M as of June 30, 2025, supporting operations.

Operating Cash Use Decreased Net cash used in operating activities decreased to $(13.507)M for six months, down from $(62.781)M previously.

Risk Factors

XOMA Merger Closing Risk Transaction completion depends on Minimum Cash Condition ($103.0M) and tender offer thresholds being met by Merger Sub.

CVR Payment Uncertainty Holders may not receive payment on Contingent Value Rights (CVRs) if specified events do not occur or CVRs expire.

Liquidity Runway Limited Existing cash supports operations for next 12 months; failure to raise capital impacts future development timelines.

Merger Restrictions Impact Operations Merger Agreement imposes limitations on business activities, asset disposal, and debt incurrence without XOMA consent.

Outlook

XOMA Acquisition Anticipated Closing Acquisition by XOMA via cash tender offer and Merger is anticipated to close in September 2025.

Continue Strategic Alternatives Review Company continues to explore and evaluate development of remaining vaccine candidates and business development activities.

Future Capital Needs Uncertain Future financing will rely on equity offerings, debt, or collaborations to fund costly clinical trial progress.

Takeda License Termination Notice Written notice delivered to terminate Takeda License; termination effective six months after notice delivery date.

Peer Comparison

Revenue (TTM)

TRML

$40.00K

-98.2%

HLVX

$0.00

-100.0%

Gross Margin (Latest Quarter)

HLVX

0.0%

+0.0pp

TRML

0.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TRML	$1.23B	-14.0	-30.5%	0.1%
HLVX	$104.76M	-1.5	-44.6%	13.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data